- In April 2023, RepliCel Life Sciences Inc., a regenerative medicine company, advanced its RCH-01 autologous cell therapy into the next phase of clinical trials in Japan and Europe, targeting long-term hair regrowth for patients with androgenetic alopecia. The therapy utilizes dermal sheath cup cells to stimulate dormant hair follicles. This progress emphasizes RepliCel’s commitment to offering innovative, biologically based treatments and highlights the growing role of regenerative medicine in reshaping hair loss management
- In March 2023, Hims & Hers Health, Inc., a prominent telehealth provider, expanded its personalized hair loss treatment offerings by launching an AI-enabled hair consultation tool. The platform tailors prescriptions of minoxidil, finasteride, and biotin supplements based on user-specific responses. This development reflects the growing demand for digital, direct-to-consumer solutions and underscores the trend toward customized, tech-driven approaches to androgenetic alopecia care
- In March 2023, DS Healthcare Group Inc. introduced Revita LASH Recovery Kit, a comprehensive system combining shampoo, serum, and a nanoxidil-based topical treatment designed to improve hair density and scalp health. This product launch builds on DS Healthcare’s strategy to offer non-invasive alternatives for early-stage hair loss, expanding its presence in both retail and clinical segments
- In February 2023, Stemson Therapeutics announced preclinical progress in developing induced pluripotent stem cell (iPSC)-derived hair follicles as part of its regenerative hair therapy platform. Targeted at severe androgenetic alopecia, this novel approach aims to generate entirely new hair follicles, offering a potential breakthrough for patients unresponsive to conventional treatments. The company’s work reinforces the global push toward curative, next-generation therapies in the hair restoration field
- In January 2023, Fagron, a global leader in personalized medicine, launched a regional compounding initiative in Southeast Asia, making customized topical treatments such as minoxidil with antiandrogens—more accessible through dermatology clinics. This initiative is part of Fagron’s strategy to expand its reach in emerging markets and meet rising demand for tailored therapies, reinforcing its role in advancing individualized treatment for androgenetic alopecia globally
